trial · primary record
Fludarabine
CD19 Positive
| Phase | Phase 1 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 18 |
| Primary completion | 2034-12-21 |
| Primary endpoint | Determine the maximum tolerated dose (MTD) of CD19-CD34t metabolically programmed CAR-T cell therapy in adult patients with CD19-positive B-cell acute lymphocytic leukemia (B-ALL). |
| Registry ID | NCT07896213 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T02:32:36.429Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07896213
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.